However, increasingly, clinical assessment of AD is now being aided by neuropathologically validated biomarkers that reflect Aβ and tau pathologies which have led to the improved accuracy in diagnosing AD during life [9, 13, 20]. The gene discussed is MAPT; the disease is Alzheimer disease.